By Lizzy Lawrence
WASHINGTON — The Food and Drug Administration, the nation’s primary arbiter of medical safety and innovation, is currently navigating a period of unprecedented institutional upheaval. In a sequence of events that has sent shockwaves through the corridors of the life sciences industry, the agency’s leadership structure is undergoing a rapid, and for many, unsettling transformation.
Following the abrupt resignation of FDA Commissioner Marty Makary, the agency is now facing a cascading series of executive departures. Among the most significant is the exit of Tracy Beth Høeg, the acting director of the Center for Drug Evaluation and Research (CDER), the massive arm of the FDA responsible for the approval and oversight of the vast majority of pharmaceutical products in the United States.
These departures represent more than just a change in personnel; they signal a pivotal shift in the agency’s strategic direction at a time when the relationship between political oversight, industry influence, and public health is under intense scrutiny.
The Core Facts: A Domino Effect in Washington
The internal memo, obtained exclusively by STAT, confirmed that Tracy Beth Høeg will be stepping down from her role as acting director of CDER. Her departure follows closely on the heels of Commissioner Marty Makary’s resignation earlier this week, which triggered a broader assessment of the agency’s senior-most ranks.
The leadership void is being filled, at least temporarily, by internal transitions. Michael Davis, who has served as the center’s deputy director, will step into the role of acting director. However, the churn is not limited to drug evaluation. Katherine Szarama, the acting director of the Center for Biologics Evaluation and Research (CBER)—which manages the oversight of vaccines, gene therapies, and blood products—is also vacating her post.
In a move that has already sparked debate regarding the revolving door between government and the private sector, the agency announced that Karim Mikhail will take over the leadership of CBER. Mikhail, who joined the FDA in 2025 as a senior adviser in the Office of the Commissioner, previously served as the CEO of the pharmaceutical firm Amarin.
A Chronology of Institutional Flux
The current turmoil did not materialize overnight. To understand the gravity of these resignations, one must look at the timeline of the past 18 months:
- Early 2025: Karim Mikhail joins the FDA as a senior adviser, signaling a new era of industry-adjacent leadership within the Office of the Commissioner.
- December 2025: Tracy Beth Høeg’s tenure at CDER becomes a flashpoint for internal tension. Reports of staff mistrust regarding the direction of the center begin to circulate, highlighting a growing divide between career scientists and political appointees.
- May 12, 2026: Commissioner Marty Makary formally tenders his resignation, leaving a void at the very top of the agency.
- May 15, 2026: The cascading effect begins in earnest. The FDA confirms that both Høeg and Szarama are departing. The immediate appointment of Michael Davis and the pivot toward Karim Mikhail are announced to stabilize the agency’s regulatory functions.
This timeline suggests that the current departures are not isolated events but rather the culmination of months of internal friction regarding how the FDA should balance its mandates to "protect" and "promote" public health.
Supporting Data: The Magnitude of the CDER and CBER Missions
To understand why these departures matter, one must consider the sheer scale of the offices now under new, temporary, or industry-influenced management.
CDER is the lifeblood of the modern pharmaceutical industry. It employs thousands of researchers, clinicians, and statisticians who determine whether a drug’s benefits outweigh its risks. According to recent agency performance reports, the center manages an annual review cycle for hundreds of New Drug Applications (NDAs) and Biologics License Applications (BLAs). Any shift in the leadership philosophy of CDER—particularly regarding the rigor of clinical trials or the speed of the "expedited approval" process—can result in billions of dollars in market valuation for pharmaceutical companies and, more importantly, life-altering consequences for patients.
CBER’s mission is arguably even more sensitive. Responsible for the safety of the nation’s blood supply and the evaluation of high-tech medical breakthroughs like mRNA vaccines and CRISPR-based gene therapies, the center acts as a gatekeeper for some of the most complex products in existence. The transition from Szarama, a career regulatory professional, to Mikhail, a former pharma CEO, represents a fundamental shift in the agency’s executive DNA.
Official Responses and Industry Reaction
The FDA has remained characteristically tight-lipped regarding the internal strife. When approached for comment, agency spokespeople reiterated that the leadership changes are intended to ensure "continuity and mission-readiness" during a time of transition.
Tracy Beth Høeg, through representatives, declined to comment on the specifics of her departure. Similarly, the Office of the Commissioner has issued standardized statements emphasizing the expertise of the incoming acting directors.
However, the silence from the top has been deafening to the rank-and-file staff. Inside the FDA, sources describe a sense of "wait and see" anxiety. Many career civil servants, who have survived multiple administration changes, are reportedly concerned that the rapid turnover suggests a desire to fast-track approvals at the expense of long-term safety data. The transition of a former CEO like Mikhail into the head of CBER has particularly energized watchdog groups who argue that the agency is losing its "firewall" against industry pressure.
Implications: What This Means for Public Health
The departure of high-ranking officials like Høeg and Szarama creates a "leadership vacuum" that is almost inevitably filled by political appointees or temporary staff who may lack the long-term institutional knowledge required to navigate the agency’s complex bureaucratic web.
1. The Politicization of Science
There is a growing concern that the FDA is becoming a tool of political messaging. When commissioners and center directors leave in quick succession, it often indicates that the "science-first" approach is being subordinated to "market-first" or "political-first" agendas. If the FDA is perceived as being "captured" by the industry it regulates, public trust in vaccine safety and drug efficacy could plummet.
2. The Revolving Door
The appointment of Karim Mikhail is the latest example of the "revolving door" phenomenon. While proponents argue that industry veterans bring necessary expertise and an understanding of the challenges of drug development, critics argue that these individuals may prioritize the interests of their former shareholders over the public interest. The challenge for Mikhail will be proving that he can act as an impartial regulator rather than an industry advocate.
3. Stability in the Marketplace
For the life sciences industry, this turnover is a double-edged sword. On one hand, a leadership shakeup may lead to a more "business-friendly" regulatory environment, where approval timelines are shortened and communication with the FDA becomes more streamlined. On the other hand, the lack of stability can cause massive uncertainty. Investors dislike volatility; if the FDA’s review standards become unpredictable due to leadership flux, the cost of capital for biotech firms may rise.
Conclusion: The Path Forward
The coming months will be critical for the FDA. With acting directors in place at the two most important centers in the agency, the burden of proof will be on the incoming leadership to demonstrate that they can maintain the rigorous standards that the American public expects.
The resignation of Commissioner Makary and the subsequent exit of his key allies suggest that the next administration will likely seek to impose a new vision on the agency. Whether that vision leads to a new golden age of innovation or a degradation of safety oversight remains the central question of the year.
For now, the hallways of the FDA’s White Oak campus remain filled with the quiet rustle of uncertainty. The agency, which has historically prided itself on being the gold standard for global regulatory science, must now prove that its foundation is strong enough to withstand the winds of political change. As for the staff—and the patients they serve—the only option is to watch closely, monitor the data, and wait to see who will be the next to lead one of the most consequential institutions in the world.
If you have information regarding the internal environment at the FDA or the policy shifts currently underway, please contact the reporter securely via Signal at lizzylaw.53.
